Catalyst Pharmaceuticals Inc. (CPRX)
Symbol Info
Listed Symbol CPRX
Name Catalyst Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $500,000
Latest Fiscal EPS $-0.34
Price Info
21 Day Moving Average $5.1300
21 Day EMA $5.218230
50 Day Moving Average $5.6982
50 Day EMA $5.327900
200 Day EMA $4.518410
200 Day Moving Average 4.275750
52 Week High $7.67
52 Week Low $1.85
52 Week Change $56.567200
Alpha 0.019214
Beta 2.4061
Standard Deviation 0.240316
R2 0.118226
Periods 60
Share Information
10 Day Average Volume 1,727,874
20 Day Average Volume 2,424,769
30 Day Average Volume 2,829,387
50 Day Average Volume 2,417,991
Outstanding Shares 102,929,257
Float Shares 93,763,415
Percent Float 91.10%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 214
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 8,200,667
Institute Holdings Percent 78.300000
Institute Sold Previous 3 Months 4,781,642
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 9,165,842
Price Change
7 Day Price Change $0.4150000
7 Day Percent Change 8.59%
21 Day Price Change $-0.0250001
21 Day Percent Change -0.47%
30 Day Price Change $-1.2950001
30 Day Percent Change -19.80%
Month To Date Price Change $-0.065
Month To Date Percent -1.22%
90 Day Price Change $1.105000
90 Day Percent Change 26.69%
Quarter To Date $-0.065
Quarter To Date Percent -1.22%
180 Day Price Change $-0.065
180 Day Percent Change -1.22%
200 Day Price Change $0.275000
200 Day Percent Change 5.53%
Year To Date $3.325000
Year To Date Percent 173.18%
Profile
Description Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.
Details
Issue Type CS
Market Cap $539,863,953
Sec Type EQS
Auditor Grant Thornton LLP
Total Shares Outstanding 102,929,257
CEO Patrick J. McEnany
Employees 51
Last Audit UQ
Classification
CIK 0001369568
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
Website http://www.catalystpharma.com
Facisimile
Telephone +1 305 420-3200
Email info@catalystpharma.com
Key Ratios
Profitability
EBIT Margin -31.2
EBITDA Margin -31.1
Pre-Tax Profit Margin -
Profit Margin Cont -10.22
Gross Margin 85.50
Profit Margin TOT -10.22
Income Statements
Revenue $41,786,338
Revenue Per Share $0.4057
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $487,723,134
Price To Sales 12.927997
Price To Free Cash -224.6
PE High Last 5 Years -
Price To Book 8.3
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 8.3
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 5.1
Leverage Ratio 1.3
Quick Ratio 5.0
Long Term Debt To Capital 0.01
Assets
Receivables Turnover 8.1
Invoice Turnover 44.30
Assets Turnover 0.50
Management Effectiveness
Return Assets -15.96
Return On Equity -18.14
Return On Capital -17.61
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
CPRX
Catalyst P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.